22 June 2020: Clinical Research
Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade
Jingjing Chen 12ACE , Shao Liu 1ADE , Hui Xu 23AF* , Wei Wang 3BC , Yanyun Xie 3B , Wenbin Tang 3B , Qiongjing Yuan 3B , Li Zheng 4D , Lizhen Lin 35F , Shuangshuang Fu 6F , Jinmei Shen 7CDOI: 10.12659/MSM.922839
Med Sci Monit 2020; 26:e922839
Table 1 Baseline characteristics of IgAN patients only with persistent hematuria initially (n=110).
| Characteristics at biopsy | All (n=110) | Treatment group (n=44) | Untreated group (n=66) | P |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Male (%) | 29 (26.4) | 12 (27.3) | 17 (25.8) | 0.86 |
| Age (years) | 30±11 | 32±11 | 29±10 | 0.16 |
| Serum creatinine (μmol/L) | 71.0 (59.0–81.0) | 72.0 (59.0–86.0) | 71.0 (58.8–77.5) | 0.26 |
| Initial eGFR (ml/min/1.73 m) | 105.5±24.4 | 102.0±22.9 | 107.9±25.2 | 0.21 |
| Hematuria, (cells/hpf) | 34.0 (17.0–66.0) | 36.0 (24.0–65.0) | 33.0 (13.0–68.0) | 0.31 |
| Systolic pressure (mmHg) | 120 (107–127) | 120 (109–128) | 118 (104–124) | 0.21 |
| Diastolic pressure (mmHg) | 75 (68–83) | 78 (70–85) | 71 (65–80) | |
| Hypertension, n (%) | 11 (10.0) | 6 (13.6) | 5 (7.6) | 0.34 |
| Hemoglobin (g/L) | 127 (118–134) | 127 (117–133) | 127 (117–134) | 0.95 |
| Albumin (g/L) | 41.9±4.5 | 41.6±4.6 | 42.1±4.4 | 0.53 |
| Uric acid (μmol/L) | 281 (249–321) | 281 (229–342) | 283 (255–309) | 0.75 |
| Low hemoglobin, n (%) | 13 (11.8) | 5 (11.4) | 8 (12.1) | 0.90 |
| Hypoalbuminemia, n (%) | 6 (5.5) | 3 (6.8) | 3 (4.5) | 0.68 |
| Hyperuricemia, n (%) | 13 (11.8) | 6 (13.6) | 7 (10.6) | 0.63 |
| Biopsy characteristics | ||||
| M1, n (%) | 57 (51.8) | 27 (61.4) | 30 (45.5) | 0.10 |
| E1, n (%) | 24 (21.8) | 8 (18.2) | 16 (24.2) | 0.45 |
| S1, n (%) | 38 (34.5) | 18 (40.9) | 20 (30.3) | 0.12 |
| T1–2, n (%) | 7 (6.4) | 2 (4.5) | 5 (7.6) | 0.70 |
| C1–2, (%)* | 12 (10.9) | 8 (18.2) | 4 (6.1) | 0.06 |
| Duration from initial diagnosis to start of therapy (months) | 5.0 (1.0–12.0) | 4.5 (1.0–16.5) | 5.6 (1.0–12.0) | 0.96 |
| * Crescents >50% were excluded. eGFR – estimated glomerular filtration rate; RASB – reninangiotensin system blockers; M – mesangial hypercellularity; E – endocapillary hypercellularity; S – segmental glomerulosclerosis; T – tubular atrophy/interstitial fibrosis; C – crescent. | ||||